Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
Telfer
Paul T
PT
Warburton
Fiona
F
Christou
Soteroula
S
Hadjigavriel
Michael
M
Sitarou
Maria
M
Kolnagou
Anita
A
Angastiniotis
Michael
M
D000328:Adult; D015913:Chelation Therapy / Q000379:methods*; D000077543:Deferiprone; D003676:Deferoxamine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007501:Iron; D007502:Iron Chelating Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011728:Pyridones / Q000627:therapeutic use*; D017262:Siderophores / Q000627:therapeutic use; D016019:Survival Analysis; D013997:Time Factors; D055815:Young Adult; D017086:beta-Thalassemia / Q000097:blood / Q000188:drug therapy*
D007502:Iron Chelating Agents; D011728:Pyridones; D017262:Siderophores; D000077543:Deferiprone; D007501:Iron; D003676:Deferoxamine